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ABSTRACT
Sex steroids are important determinants of bone acquisition and bone homeostasis. Cross-sex hormonal treatment (CHT) in
transgender persons can affect bone mineral density (BMD). The aim of this study was to investigate in a prospective observational
multicenter study the ﬁrst-year effects of CHT on BMD in transgender persons. A total of 231 transwomen and 199 transmen were
includedwho completed the ﬁrst year of CHT. Transwomenwere treated with cyproterone acetate and oral or transdermal estradiol;
transmen received transdermal or intramuscular testosterone. A dual-energy X-ray absorptiometry (DXA) was performed tomeasure
lumbar spine (LS), total hip (TH), and femoral neck (FN) BMDbefore and after 1 year of CHT. In transwomen, an increase in LS (þ3.67%,
95% conﬁdence interval [CI] 3.20 to 4.13%, p< 0.001), TH (þ0.97%, 95% CI 0.62 to 1.31%, p< 0.001), and FN (þ1.86%, 95% CI 1.41 to
2.31%, p< 0.001) BMD was found. In transmen, TH BMD increased after 1 year of CHT (þ1.04%, 95% CI 0.64 to 1.44%, p< 0.001). No
changes were observed in FN BMD (–0.46%, 95% CI –1.07 to 0.16%, p¼ 0.144). The increase in LS BMD was larger in transmen aged
50 years (þ4.32%, 95% CI 2.28 to 6.36%, p¼ 0.001) compared with transmen aged <50 years (þ0.68%, 95% CI 0.19 to 1.17%,
p¼ 0.007). In conclusion, BMD increased in transgender persons after 1 year of CHT. In transmen of postmenopausal age, the LS BMD
increasedmore than in younger transmen, whichmay lead to the hypothesis that the increase in BMD in transmen is the result of the
aromatization of testosterone to estradiol. © 2017 American Society for Bone and Mineral Research.
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Introduction
Gender dysphoria (GD) is deﬁned as the sufferance related toan incongruence between one’s experienced and one’s
assigned gender of a duration of at least 6 months.(1) Persons
who experience gender-related distress might desire gender-
afﬁrming treatment with sex steroids. Sex steroids are also
important determinants of bone acquisition and bone
homeostasis.
In natal men, testosterone stimulates the process of periosteal
apposition, leading to a greater cortical bone size and wider
bones than in women.(2,3) Men with aromatase deﬁciency have
been found to have lower bonemass, indicating that estrogen is
an important regulator of bone acquisition inmen.(4–6) However,
the effect of testosterone on bone mineral density (BMD) is less
clear.
In natal women, estrogen inhibits periosteal apposition but
stimulates endosteal bone formation.(7) Loss of estrogen at
menopause leads to an increased osteoclastic activity and
therefore accelerated bone loss.(8,9) In women with polycystic
ovary syndrome with hyperandrogenism, an increased trabecu-
lar BMD has been found, even after adjustment for body
mass.(10) In addition, women with complete androgen insensi-
tivity syndrome (46,XY karyotype) have been found to have
lower BMD,(11) which might indicate that testosterone also
regulates BMD in women.
Cross-sex hormonal treatment (CHT) in transgender persons
causes changes in gonadal hormone levels in order to achieve
desired body changes. Transwomen (male-to-female trans-
genders) receive estrogen and anti-androgens, whereas
transmen (female-to-male transgenders) are treated with
testosterone. Although a few studies have investigated the
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effects of CHT on BMD, most of these studies were cross-
sectional or had small sample sizes with inconclusive or
contradictory results.(12–19) The aim of this study is therefore
to investigate, in a large multicenter prospective cohort,
whether CHT inﬂuences BMD in transwomen and transmen
during the ﬁrst year of treatment.
Materials and Methods
Study design and population
This study is part of the European Network for Investigation of
Gender Incongruence (ENIGI) study, a multicenter prospec-
tive observational study performed for its endocrine part
in Ghent (Belgium), Oslo (Norway), Florence (Italy), and
Amsterdam (the Netherlands).(20,21) Trans persons aged
18 years and older who started CHT between 2010 and
April 2016 after a conﬁrmed GD diagnosis(1) were asked to
participate in the study. Exclusion criteria were prior cross-sex
hormone use, psychological vulnerability, the occurrence of
protocol deviations (eg, the use of gonadotropin-releasing
hormone agonist or spironolactone), or insufﬁcient knowl-
edge of the native language. For the present analysis, only
persons who completed the ﬁrst year of CHT were included.
Because the participating centers used different types of
dual-energy X-ray absorptiometry (DXA) scanners (Ghent and
Amsterdam: Hologic Discovery A [Hologic Inc, Bedford, MA,
USA]; Florence: Hologic Delphi A; Oslo: Lunar [GE Lunar,
Madison, WI, USA]), non-comparable BMD values were
obtained. Consequently, only persons with BMD measure-
ments performed in either Ghent or Amsterdam were
included in the analyses. Persons who did not have a
baseline DXA scan or had a baseline DXA scan outside the
window of 3 months before or 1 month after the start of CHT
were excluded. In addition, persons who did not have a
follow-up DXA scan or had a follow-up scan before 10 or after
14 months after the start of CHT were excluded.
All trans persons were treated according to the Standards of
Care Guidelines of the World Professional Association for
Transgender Health (WPATH).(22) Transwomen received cyprot-
erone acetate (50 to 100mg daily) combined with oral estradiol
valerate (2 to 4mg daily) or an estradiol patch (50 to 100mg
twice a week). Transmen were treated with testosterone gel
(50mg daily), intramuscular testosterone esters (250mg every
2 weeks), or intramuscular testosterone undecanoate (1000mg
every 12 weeks).
This study was conducted in accordance with the Declara-
tion of Helsinki, and the overall study protocol was approved
by the Ethical Review Board of the Ghent University Hospital,
Belgium. In the other participating centers, approval for
participation was also obtained by the local ethical commit-
tees. Study participants gave informed consent according to
institutional guidelines.
Clinical data collection
During the ﬁrst year of treatment, trans persons visited the
outpatient endocrine unit once every 3 months, where they
reported their medical history, medication use, smoking habits
(in cigarettes per day), and alcohol use (in units per week).
Physical examination was performed bymeasuring body weight
(in kilograms) and height (in meters) in indoor clothing without
shoes.
Biochemical assessment
Blood samples were drawn at baseline, after 3 months, and after
12 months of CHT, all after overnight fasting. In Amsterdam,
estradiol was measured using a competitive immunoassay
(Delﬁa, PerkinElmer, Turku, Finland) with an interassay coefﬁ-
cient of variation (CV) of 10% to 13% and a lower limit of
quantitation (LOQ) of 20 pmol/L until July 2014. After July 2014,
estradiol was measured using a LC-MS/MS (VUmc, Amsterdam,
the Netherlands) with an interassay CV of 7% and a LOQ of
20 pmol/L. For conversion of the Delﬁa values, the formula LC-
MS/MS¼ 1.60  Delﬁa–29 was used. Testosterone was measured
using a radioimmunoassay (RIA) (Coat-A-Count, Siemens, Los
Angeles, CA, USA) with an interassay CV of 7% to 20% and a LOQ
of 1 nmol/L until January 2013. Thereafter, testosterone was
measured using competitive immunoassay (Architect, Abbott,
Abbott Park, IL, USA) with an interassay CV of 6% to 10% and a
LOQ of 0.1 nmol/L. The RIA values were converted to the
competitive immunoassay values. For testosterone levels below
8 nmol/L, the formula Architect¼ 1.1  RIAþ 0.2 was used;
for testosterone levels above 8 nmol/L, the formula Architect
¼ 1.34  RIA – 1.65 was used. 25-hydroxyvitamin D (25(OH)D)
was measured using LC-MS/MS as described previously.(23)
In Ghent, estradiol was measured using a E170 Modular (Gen
II, Roche Diagnostics, Mannheim, Germany) until March 19,
2015. Thereafter, estradiol was measured using a E170 Modular
(Gen III, Roche Diagnostics), with an interassay CV of 3.2% and
a LOQ of 25 pg/mL (92 pmol/L). For conversion of estradiol
values measured before March 19, 2015, the formula Gen
III¼ 6.687940þ 0.834495  Gen II was used. E170 Modular
(Roche Diagnostics, Germany) was used to measure testoster-
one (Gen II) and 25(OH)D, with an interassay CV of 2.6% and a
LOQ of 10 ng/dL (0.4 nmol/L) for testosterone, and an interassay
CV of 6.7% and a LOQ of 5 ng/mL (12.5 nmol/L) for 25(OH)D.
Bone mineral density
DXA was performed at baseline and after one year CHT. In both
Ghent and Amsterdam, a Hologic Discovery A was used (Hologic
Inc). In Ghent, software version 12.7.3.1 was used. In Amsterdam,
the software version was updated from 13.3 to 13.5.3 in
July 2015. The Hologic Statement of Equivalency allowed for
comparison of absolute BMD values between the different scan
dates and times. Absolute BMD values were obtained for lumbar
spine (LS, L1 to L4), non-dominant total hip (TH), and femoral
neck (FN).
Statistical analysis
The baseline characteristics of both transwomen and transmen
are reported as medians (interquartile range [IQR]) or percen-
tages. Differences between included and excluded personswere
analyzed using independent t tests (orWilcoxon rank-sum test in
case of non-normal distribution) or chi-square tests. Difference
between BMD values obtained in Amsterdam and Ghent
were analyzed using an independent t test. Data were log-
transformed before further analysis in case of non-normal
distribution. For all analyses, individuals with missing values
were excluded. Percentage changes in LS, TH, and FN BMD after
1 year of CHT were calculated for every person, and as these
were normally distributed continuous variables, linear regres-
sion analyses were performed to generate the mean percentage
changes with corresponding 95% conﬁdence intervals (CI) and
p values.
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Analyses were stratiﬁed for age groups (18–20, 21–29, 30–49,
and50 years) in order to stratify for accrual of peak bonemass,
peak bone mass, age-related decrease in bone mass, and, in
transmen, for postmenopausal state. Analyses were stratiﬁed for
the use of vitamin D supplementation, as persons with vitamin D
deﬁciency were treated with vitamin D supplementation. For
analyses on different estradiol or testosterone administration
routes, only transmen and transwomen who used the same
administration route and dose during the entire year were
included. Difference between age groups, vitamin D supple-
mentation, or administration routes were analyzed using linear
regression analyses with percentage change in BMD as outcome
variable and age groups, vitamin D supplementation, or
administration routes as categorical independent variables,
respectively. To adjust for possible mediating factors, linear
regression analyses were performed between percentage
change in BMD and change in body weight, and between
percentage change in BMD and change in cigarette and alcohol
use. The change in alcohol or cigarette use was calculated as the
percentage difference in number of cigarettes or units of alcohol
between baseline and the 12-month visit. To investigate the
inﬂuence of the serum concentrations of sex steroids on BMD
change, linear regression analyses were performed between the
change in BMD and the mean serum estradiol or testosterone
levels after 3 to 12months of CHT, and were analyzed separately
for Amsterdam and Ghent, as no conversion formulas were
available for the sex steroid assays. Sensitivity analyses were
performed by repeating the analyses after exclusion of all
persons with comorbidities or medication use with possible
inﬂuence on BMD. Analyses were performed with STATA




The ﬂowchart of the inclusion of participants in both centers is
shown in Fig. 1. In total, 231 transwomen and 199 transmen
were included for analyses. The baseline characteristics are
shown in Table 1. Except for a younger age in excluded transmen
(median age 22 years, IQR 20 to 27) compared with included
transmen (median age 24 years, IQR 21 to 31, difference
p¼ 0.004), no baseline differences were found in weight, BMI,
ethnicity, smoking habits, alcohol use, estradiol levels, testos-
terone levels, and vitamin D levels between persons excluded
and included for analyses.
Bone mineral density
The mean time between two DXA scans was 12 months (range
10 to 14 months). No differences in baseline BMD and 12-month
BMD between the two included centers were found (Table 2).
In transwomen, 1-year CHT increased BMD of the LS (þ3.67%,
95% CI 3.20 to 4.13%, p< 0.001), TH (þ0.97%, 95% CI 0.62 to
1.31%, p< 0.001), and FN (þ1.86%, 95% CI 1.41 to 2.31%,
p< 0.001). In transmen, 1-year CHT increased LS and TH BMD
(þ0.86%, 95% CI 0.38 to 1.35%, p¼ 0.001, and þ1.04%, 95% CI
0.64 to 1.44%, p< 0.001, respectively). No changes were
Fig. 1. Flowchart of the inclusion of participants in the present study. DXA¼dual-energy X-ray absorptiometry.
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observed in FN BMD (–0.46%, 95% CI –1.07 to 0.16%, p¼ 0.144)
(Fig. 2).
Effects of weight change on BMD change
Transwomen had a mean weight increase of 2.4 kg (95% CI 1.5
to 3.2 kg, p< 0.001). The gain in LS BMD did not change after
adjustment for change in body weight (þ3.64%), but an
attenuation of TH (þ0.65%) and FN (þ1.52%) BMD change was
found. Transmen had a mean weight increase of 2.0 kg (95% CI
1.2 to 2.8 kg, p< 0.001). After adjustment for change in body
weight, the mean increase of LS (þ0.90%) and FN (–0.87%)
BMD did not change, but an attenuation of TH (þ0.86%) BMD
change was found.
Effects of change in cigarette or alcohol use on BMD
change
A total of 52.1% and 27.5% of the transwomen who either
smoked cigarettes or drank alcohol at baseline quit smoking
and stopped using alcohol, respectively. Adjusting the
analyses for percentage change in cigarette or alcohol use
did not change the results of LS (þ3.80%), TH (þ0.92%), or FN
(þ1.91%) BMD change. Of the transmen, 45.6% and 28.7% who
Table 1. Baseline Characteristics of Transwomen and Transmen
Transwomen (n¼ 231) Transmen (n¼ 199)
Age (years [IQR]) 28 (23 to 42) 24 (21 to 31)
Ethnicity (% white) 97.4 94.0
BMI (kg/m2 [IQR]) 22.5 (20.5 to 26.1) 23.9 (21.3 to 28.8)
Tobacco use (% yes) 23.5 29.3
Cigarettes per day (IQR) 10 (5 to 12) 10 (5 to 15)
Alcohol use (% >7 units per week) 6.1 4.6
Biochemical results Amsterdam (IQR)a
Estradiol levels (pmol/L) 105 (82 to 133) 169 (61 to 377)
Testosterone levels (nmol/L) 18.5 (14.0 to 23.0) 1.3 (1.0 to 1.7)
25(OH) vitamin D levels (nmol/L) 38 (24 to 57) 54 (31 to 77)
Biochemical results Ghent (IQR)b
Estradiol levels (pmol/L) 114 (95 to 135) 155 (114 to 301)
Testosterone levels (nmol/L) 19.0 (13.5 to 22.2) 1.1 (0.7 to 1.3)
25(OH) vitamin D levels (nmol/L) 34 (22 to 52) 54 (36 to 72)
IQR¼ interquartile range; BMI¼body mass index.
Data are expressed as median (interquartile range) or percentages.
aTranswomen n¼ 135; transmen n¼ 137.
bTranswomen n¼ 93; transmen n¼ 41.
Table 2. Baseline and 1 Year BMD in Lumbar Spine, Total Hip, and Femoral Neck for Transwomen and Transmen, Stratiﬁed per Center
Amsterdam Ghent Total p Values
Transwomen (n¼ 137) (n¼ 94) (n¼ 231)
Lumbar spine BMD
Baseline 0.966 (0.138) 0.983 (0.143) 0.972 (0.140) 0.362
1 year 1.001 (0.137) 1.015 (0.143) 1.007 (0.139) 0.470
Total hip BMD
Baseline 0.938 (0.133) 0.939 (0.135) 0.938 (0.134) 0.942
1 year 0.948 (0.133) 0.946 (0.138) 0.947 (0.135) 0.905
Femoral neck BMD
Baseline 0.798 (0.124) 0.799 (0.133) 0.799 (0.128) 0.960
1 year 0.814 (0.127) 0.811 (0.135) 0.813 (0.130) 0.834
Transmen (n¼ 155) (n¼ 44) (n¼ 199)
Lumbar spine BMD
Baseline 1.030 (0.124) 1.022 (0.114) 1.028 (0.121) 0.705
1 year 1.039 (0.126) 1.027 (0.108) 1.037 (0.122) 0.554
Total hip BMD
Baseline 0.954 (0.113) 0.945 (0.130) 0.952 (0.116) 0.646
1 year 0.963 (0.114) 0.958 (0.129) 0.962 (0.117) 0.815
Femoral neck BMD
Baseline 0.837 (0.116) 0.833 (0.112) 0.836 (0.115) 0.805
1 year 0.831 (0.116) 0.834 (0.117) 0.832 (0.116) 0.908
BMD¼bone mineral density.
Numbers represent absolute bone mineral density in g/cm2 (standard deviation). Independent t tests were performed between the Amsterdam and
Ghent data.
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either smoked cigarettes or drank alcohol at baseline quit
smoking and stopped using alcohol, respectively. No changes
were observed in LS (þ0.93%), TH (þ1.24%), and FN (–0.50%)
BMD change after adjustment for change in cigarette or
alcohol use.
The effect of age on BMD change
As shown in Fig. 3, the change in LS, TH, or FN BMD in
transwomen did not vary in different age groups, except for a
larger increase in LS BMD in transwomen of aged 18 to
20 years compared with transwomen of 30 to 49 years. In
transmen, LS BMD increased more in persons aged 50 years
(þ4.32%, 95% CI 2.28 to 6.36%, p¼ 0.001) compared with
persons younger than 50 years (þ0.68%, 95% CI 0.19 to
1.17%, p¼ 0.007). The geometric mean estradiol levels
increased from 14 pmol/L to 150 pmol/L (þ949%, 95% CI
304 to 2629%, p< 0.001) in persons aged 50 years
compared with no increase in persons younger than 50 years
(158 pmol/L to 194 pmol/L; þ22%, 95% CI –2 to 53%,
p¼ 0.078).
The effect of vitamin D supplements on BMD change
As shown in Fig. 4, LS and FN BMD increased more in
transwomen who used vitamin D supplements compared
with those who did not use supplements. No differences were
found in TH BMD change. In transmen, no differences in LS, TH,
and FN BMD change were found between persons with or
without vitamin D supplementation.
Correlation of BMD change with sex hormone levels
After 3 to 12 months of CHT, the estradiol levels of
transwomen in Amsterdam were correlated with LS (per
100 pmol/L: þ0.95%, 95% CI 0.34 to 1.56%, p¼ 0.003), TH (per
100 pmol/L: þ0.48%, 95% CI 0.04 to 0.93%, p¼ 0.034), and FN
(per 100 pmol/L: þ0.83%, 95% CI 0.31 to 1.36%, p¼ 0.002)
BMD change. The estradiol levels after 3 to 12 months in
transwomen in Ghent were correlated with LS (per 100 pmol/L:
þ0.87%, 95% CI 0.27 to 1.47%, p¼0.005), but not with TH (per
100 pmol/L: þ0.40%, 95% CI –0.12 to 0.92%, p¼ 0.126) or FN
(per 100 pmol/L: þ0.09%, 95% CI –0.67 to 0.85%, p¼ 0.814)
BMD change. In transmen in Amsterdam and Ghent, estradiol
levels after 3 to 12 months were not correlated with BMD
change. Because testosterone levels after 3 to 12 months were
suppressed in transwomen, no correlation analyses could be
performed. In transmen, testosterone levels after 3 to
12 months were not correlated with LS, TH, and FN BMD
change.
The effect of estradiol or testosterone administration
routes on BMD change
LS, TH, or FN BMD change did not differ between transdermal
estradiol or oral estradiol valerate use in transwomen (Fig. 4).
Serum estradiol levels were comparable between transdermal
estradiol (ref) and oral estradiol valerate (difference –7 pmol/L,
95% CI –50 to 36 pmol/L, p¼ 0.754).
In transmen, no differences in LS and TH BMD change was
observed between testosterone gel, testosterone esters, or
testosterone undecanoate. FN BMD change was higher in
testosterone undecanoate compared with testosterone gel
(Fig. 4). Testosterone levels were comparable between testos-
terone gel (ref) and testosterone undecanoate (–3.5 nmol/L, 95%
CI –12.9 to 5.9 nmol/L, p¼ 0.459), whereas testosterone esters
provided higher testosterone levels than testosterone gel
(þ13.0 nmol/L, 95% CI 6.2 to 19.9 nmol/L, p< 0.001).
Sensitivity analyses
Repeating the analyses after exclusion of all persons with bone-
inﬂuencing medication (use of diuretics [n¼ 6], anti-epileptics
[n¼ 3], antidepressants [n¼ 58], antipsychotics [n¼ 9], cortico-
steroids [n¼ 15], or bisphosphonates [n¼ 1]) or comorbidities
(eating disorder [n¼ 4], alcohol abuse [n¼ 4], thyroid disease
[n¼ 5], diabetes mellitus [n¼ 5], gastrointestinal disease [n¼ 8],
malignancy [n¼ 2]) did not change the effect sizes (data not
shown).
Discussion
This study showed that after 1 year of CHT the mean BMD
increased in both transwomen and transmen, especially in
lumbar spine and in transwomen. In transmen of postmeno-
pausal age, the LS BMD increased more than in younger
transmen. In both transwomen and transmen, the change in
BMD could not be completely explained by a change in body
weight, a change in cigarette or alcohol use, or by vitamin D
supplementation.
Fig. 2. Change in bone mineral density (BMD) of the lumbar spine, total
hip, and femoral neck in transwomen and transmen after 1 year of cross-
sex hormonal treatment. Data representmean baseline andmean 1-year
BMD with standard deviation. Percentage changes in BMD were
calculated for every person, and because these were normally
distributed continuous variables, linear regression analyses were
performed to generate the mean percentage changes with correspond-
ing 95% conﬁdence intervals (CI), which are shown in the legends on the
right. p  0.001. BMD¼bone mineral density.
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The larger increase in BMD in transmen of postmenopausal
age compared with the other age groups may be the result of
decreased bone resorption due to higher levels of estradiol
after aromatization of testosterone to estradiol, as serum
estradiol levels were low at baseline and largely increased
during CHT. These ﬁndings may lead to the hypothesis that
the increase in bone mineral density in older transmen is the
result of aromatization of testosterone to estradiol and
therefore an increase in estradiol levels, instead of direct
effects of testosterone. This is in line with Finkelstein and
colleagues,(24) who demonstrated that effects of hypogonad-
ism on bone in men are mainly due to estrogen deﬁciency and
not to testosterone deﬁciency. In addition, the results are
compatible with ﬁndings in older natal men, whose BMD is
better correlated with bioavailable estradiol levels than with
other sex steroid measures.(25) However, it is not known
whether these ﬁndings can be extrapolated to transmen. The
larger increase in LS BMD in transwomen aged 18 to 20 years
compared with transwomen aged 30 to 49 years could be
explained by the fact that the youngest group has not reached
the peak bone mass yet and therefore the increase in BMD
is larger.
In both transwomen and transmen, the TH BMD increase
attenuated after adjustment for change in body weight,
Fig. 3. Change in bonemineral density of lumbar spine, total hip, and femoral neck in transwomen and transmen, stratiﬁed for age groups. Each individual
bar represents the mean increase in bone mineral density with 95% conﬁdence interval. The age distribution in transwomen is: 18–20 (n¼ 36), 21–29
(n¼ 88), 30–49 (n¼ 83), and 50 (n¼ 24) years; in transmen: 18–20 (n¼ 56), 21–29 (n¼ 87), 30–49 (n¼ 46), and50 (n¼ 10) years. Differences between
these age groups were analyzed using linear regression analyses, with percentage change in BMD as outcome variable and age groups as categorical
dependent variable. p 0.001; 0.001< p 0.01; 0.01< p 0.05. LS¼ lumbar spine; TH¼ total hip; FN¼ femoral neck; BMD¼bone mineral density.
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indicating that the increase in hip BMD is partly mediated by
an increase in body weight. No differences in BMD change
were observed between administration routes of estradiol or
testosterone, except a small difference in FN BMD change
between testosterone gel and testosterone undecanoate.
However, the groups of testosterone administration routes
were small and the analysis might not have enough power to
detect small differences. No differences were observed in
mean estradiol levels between transdermal estradiol or
estradiol valerate. Testosterone esters gave higher testoster-
one levels compared with testosterone gel and testosterone
undecanoate. However, testosterone ester therapy results in
highly ﬂuctuating serum testosterone levels, and because
blood determination was independent of the last injection of
testosterone esters, no representative testosterone levels
were obtained from persons using testosterone esters. The
current using dose of testosterone esters is thought to be
similar to the dose of testosterone gel and testosterone
undecanoate.(26)
Previously, small prospective studies were performed to
investigate the change in BMD in transgender persons after
1 year of CHT. For transwomen, our results are comparable to
most other studies, as an increase in LS BMD was found in
transwomen treated with anti-androgens and estrogens(18,27,28)
or treated with estrogens and gonadotropin-releasing hormone
agonists.(13,29) One prospective study did not ﬁnd a change in
BMD in 12 transwomen.(30) Although the same results were
found inmost other studies, our results cannot be generalized to
all parts of the world, as the included transwomen used
cyproterone acetate and this is not approved for use in the
United States.
We found different results for the change in BMD in transmen
than described in literature. Although previous prospective
studies did not ﬁnd a change in LS BMD after 1 year of
CHT,(14,19,27,28,30) we found a small increase in the total group
and even a larger increase in the postmenopausal subgroup.
This difference might be because of the small sample sizes of
other studies and consequently lack of power to allow these
studies to detect any differences. In addition, a subgroup
analysis of the change in BMD in postmenopausal transmen has
not been described before, as transmen included in previously
mentioned studies were 18 to 47 years,(19) 16 to 39 years,(28) and
20 to 46 years(30) of age.
This study is a large multicenter prospective study,
including transwomen and transmen with a wide range of
age. All trans persons were treated according to a deﬁned
treatment protocol, and measurements were performed at
baseline and during follow-up. Only a small percentage of
participants were lost to follow-up (8.5%). There are also
some limitations to our study. First, because of the
multicenter aspect of this study, the BMD of participants
was measured using different DXA devices. To compare the
baseline values, Oslo and Florence were excluded for the
present analyses and only Ghent and Amsterdam were
included. Each individual had a baseline and follow-up BMD
measurements on the same DXA device, and no differences
were observed between Ghent and Amsterdam. Between the
study centers, different laboratory assays were used, and
within one study center, the assay was adjusted when more
accurate assays became available. Conversion formulas
within one center allowed for comparison of the data.
However, because no conversion formulas between the
centers were available, the analysis had to be stratiﬁed by
center. The associations found within both centers were
similar, which allows for higher generalizability of the results.
Second, the study was performed during regular patient care.
Data about smoking habits, alcohol use, medication use, and
comorbidities were self-reported and were collected during
their outpatient clinic visits. It is possible that some
medication use or comorbidities were not reported, includ-
ing the use of additional testosterone or estradiol prepara-
tions next to the prescribed sex hormones. Third, no data
about physical exercise or calcium intake was available.
Persons with low baseline BMD were advised about factors of
positive inﬂuence on BMD, including exercise, calcium intake,
and vitamin D supplements. Therefore, we cannot prove that
the increase in BMD is solely a result of CHT. Because of
ethical and practical reasons, it is not possible to add a
placebo group to this study. Fourth, because this study is
only performed in trans persons without a control group, we
cannot rule out that passing time is partly an explanation for
the change in BMD. However, because most persons had
already reached the age of peak bone mass achievement at
the time of inclusion in the study, the natural course of BMD
Fig. 4. Change in bone mineral density (BMD) of the lumbar spine, total
hip, and femoral neck in transwomen and transmen, stratiﬁed for
vitamin D supplementation or administration routes, respectively. Linear
regression analyses with change in BMD as outcome variable and
vitamin D supplementation or administration route as independent
variable were performed. Only persons using the same dose and
administration route during the entire year were included for analyses.
p  0.001; 0.01 < p 0.05. LS¼ lumbar spine; TH¼ total hip;
FN¼ femoral neck; BMD¼bone mineral density; T¼ testosterone.
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is to decrease over time. Lastly, for the present analyses, we
only assessed BMD using a DXA scan, which does not provide
any information about bone geometry. Further research is
needed into whether changes in bone geometry can be
found after CHT. However, in regular patient care, BMD is also
assessed using a DXA scan; therefore, this study may be
valuable for clinical practice.
One study reported a lower BMD in transwomen at the start of
CHT compared with age-matched control men.(31) Hormonal
treatment may inﬂuence the achievement of higher BMD on
short term. A healthier lifestyle including more exercise and
vitamin D exposure may also contribute to this change in BMD.
Therefore, with regard to the clinical practice, monitoring bone
quality in trans persons is relevant.
In conclusion, an increase in BMD in both transwomen
and transmen after 1 year of CHT was found. For further
research, it is desirable to investigate alterations in BMD
after long-term CHT, to monitor bone turnover markers, and
to add other imaging modalities to gain more insight into
the actual changes in bone metabolism due to sex steroid
therapy.
Disclosures
All authors state that they have no conﬂicts of interest.
Acknowledgments
Authors’ roles: Study design: ADF, TS, GT, and MdH. Study
conduct: GT and MdH. Data collection: CMW, MCV, MK, NMN,
CJMdB, ADF, TS, GT, and MdH. Data analysis: CMW and MCV.
Data interpretation: CMW and MCV. Drafting manuscript: CMW.
Revising manuscript content: CMW, MCV, MK, NMN, CJMdB,
RTdJ, PL, GT, and MdH. Approving ﬁnal version of manuscript:
CMW, MCV, MK, NMN, CJMdB, ACH, RTdJ, PL, ADF, TS, GT, and
MdH. MdH takes responsibility for the integrity of the data
analysis.
References
1. American Psychiatric Association. Diagnostic and statistical manual
of mental disorders. 5th edition, text revision (DSM-5). Arlington, VA:
American Psychiatric Publishing; 2013.
2. Venken K, De Gendt K, Boonen S, et al. Relative impact of androgen
and estrogen receptor activation in the effects of androgens on
trabecular and cortical bone in growing male mice: a study in the
androgen receptor knockout mouse model. J Bone Miner Res.
2006;21(4):576–85.
3. Zamberlan N, Radetti G, Paganini C, Gatti D, Rossine M, Braga V,
Adami S. Evaluation of cortical thickness and bone density by
roentgen microdensitometry in growing males and females. Eur J
Pediatr. 1996;155(5):377–82.
4. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in
a man with aromatase deﬁciency. N Engl J Med. 1997;337(2).
5. Herrmann BL, Janssen OE, Hahn S, Broecker-Preuss M, Mann K.
Effects of estrogen replacement therapy on bone and glucose
metabolism in a male with congenital aromatase deﬁciency. Horm
Metab Res. 2005;37:178–83.
6. Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone
mass as a result of estrogen therapy in a man with aromatase
deﬁciency. N Engl J Med. 1998;339(9):599–603.
7. Kim B, Mosekilde L, Duan Y, et al. The structural and hormonal basis
of sex differences in peak appendicular bone strength in rats. J Bone
Miner Res. 2003;18(1):150–5.
8. Greendale GA, Sowers M, Han W, et al. Bone mineral density loss in
relation to the ﬁnal menstrual period in a multiethnic cohort: results
from the Study ofWomen’s Health Across the Nation (SWAN). J Bone
Miner Res. 2012;27(1):111–8.
9. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss
via estrogen receptor alpha and induction of Fas ligand in
osteoclasts. Cell. 2007;130(5):811–23.
10. Buchanan JR, Hospodar P, Myers C, Leuenberger P, Demers LM.
Effect of excess endogenous androgens on bone density in young
women. J Clin Endocrinol Metab. 1988;67(5):937–43.
11. Bertellonia S, Baroncellia GI, Federicoa G, Cappab M, Lalac R,
Saggesea G. Altered bone mineral density in patients with complete
androgen insensitivity syndrome. Horm Res. 1998;50:309–14.
12. Dittrich R, Binder H, Cupisti S, Hoffmann I, BeckmannMW, Mueller A.
Endocrine treatment of male-to-female transsexuals using gonado-
tropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes.
2005;113(10):586–92.
13. Mueller A, Dittrich R, Binder H, Kuehnel W, Maltaris T, Hoffmann I,
Beckmann MW. High dose estrogen treatment increases bone
mineral density in male-to-female transsexuals receiving gonado-
tropin-releasing hormone agonist in the absence of testosterone.
Eur J Endocrinol. 2005;153(1):107–13.
14. Mueller A, Haeberle L, Zollver H, et al. Effects of intramuscular
testosterone undecanoate on body composition and bone
mineral density in female-to-male transsexuals. J Sex Med. 2010;
7(9):3190–8.
15. Mueller A, Zollver H, Kronawitter D, et al. Body composition and
bone mineral density in male-to-female transsexuals during cross-
sex hormone therapy using gonadotrophin-releasing hormone
agonist. Exp Clin Endocrinol Diabetes. 2011;119(2):95–100.
16. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-
sex hormone treatment in transsexual persons. J Sex Med. 2012;
9(10):2641–51.
17. Van Caenegem E, Wierckx K, Taes Y, et al. Bone mass, bone
geometry, and body composition in female-to-male transsexual
persons after long-term cross-sex hormonal therapy. J Clin Endo-
crinol Metab. 2012;97(7):2503–11.
18. Van Caenegem E, Wierckx K, Taes Y, et al. Preservation of volumetric
bone density and geometry in trans women during cross-sex
hormonal therapy: a prospective observational study. Osteoporos
Int. 2015;26(1):35–47.
19. Van Caenegem E, Wierckx K, Taes Y, et al. Body composition, bone
turnover, and bone mass in trans men during testosterone
treatment: 1-year follow-up data from a prospective case-controlled
study (ENIGI). Eur J Endocrinol. 2015;172(2):163–71.
20. Dekker MJHJ, Wierckx K, Van Caenegem E, et al. A EuropeanNetwork
for the Investigation of Gender Incongruence: endocrine part. J Sex
Med. 2016;13(6):994–9.
21. Kreukels BP, Haraldsen IR, De Cuypere G, Richter-Appelt H, Gijs L,
Cohen-Kettenis PT. A European network for the investigation of
gender incongruence: the ENIGI initiative. Eur Psychiatry. 2012;
27(6):445–50.
22. The World Professional Association for Transgender Health. Stand-
ards of care for the health of transsexual, transgender, and gender-
nonconforming people. Version 7. Elgin, IL: WPATH; 2012.
23. Heijboer AC, Blankenstein MA, Kema IP, Buijs MM. Accuracy of
6 routine 25-hydroxyvitamin D assays: inﬂuence of vitamin D
binding protein concentration. Clin Chem. 2012;58(3):543–8.
24. Finkelstein JS, Lee H, Leder BZ, et al. Gonadal steroid-dependent
effects on bone turnover and bone mineral density in men. J Clin
Invest. 2016;126(3):1114–25.
25. Cauley JA, Ewing SK, Taylor BC, et al. Sex steroid hormones in older
men: longitudinal associations with 4.5-year change in hip bone
mineral density—the osteoporotic fractures in men study. J Clin
Endocrinol Metab. 2010;95(9):4314–23.
26. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone
replacement therapy preparations. Transl Androl Urol. 2016;
5(6):834–43.
27. Van Kesteren P, Lips P, Deville W, et al. The effect of one-year cross-
sex hormonal treatment on bonemetabolism and serum insulin-like
Journal of Bone and Mineral Research INCREASE OF BMD IN TRANS PERSONS AFTER 1-YEAR CHT 1259
growth factor-1 in transsexuals. J Clin Endocrinol Metab. 1996;
81(6):2227–32.
28. van Kesteren P, Lips P, Gooren LJ, Asscheman H, Megens J. Long-
term follow-up of bone mineral density and bone metabolism in
transsexuals treated with cross-sex hormones. Clin Endocrinol.
1998;48:347–54.
29. Mueller A, Zollver H, Kronawitter D, et al. Body composition and
bone mineral density in male-to-female transsexuals during
cross-sex hormone therapy using gonadotrophin-releasing hor-
mone agonist. Exp Clin Endocrinol Diabetes. 2011;119(2):95–100.
30. Haraldsen IR, Haug E, Falch J, Egeland T, Opjordsmoen S. Cross-sex
pattern of bone mineral density in early onset gender identity
disorder. Horm Behav. 2007;52(3):334–43.
31. Van CaenegemE, Taes Y,Wierckx K, et al. Low bonemass is prevalent
in male-to-female transsexual persons before the start of cross-sex
hormonal therapy and gonadectomy. Bone. 2013;54(1):92–7.
1260 WIEPJES ET AL. Journal of Bone and Mineral Research
